APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Myeloid Leukemia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Acute Myeloid Leukemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchAcute Myeloid Leukemia Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Myeloid Leukemia Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Acute Myeloid Leukemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Myeloid Leukemia Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Myeloid Leukemia Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Acute Myeloid Leukemia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Acute Myeloid Leukemia Drugs include Takeda Pharmaceuticals, Eisai, Novartis, Eli Lilly and Company, Sunesis Pharmaceuticals, Otsuka Holdings, Genzyme Corporation, Clavis Pharma and Cephalon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Acute Myeloid Leukemia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Myeloid Leukemia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Myeloid Leukemia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Acute Myeloid Leukemia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Acute Myeloid Leukemia Drugs Segment by Company

Takeda Pharmaceuticals

Eisai

Novartis

Eli Lilly and Company

Sunesis Pharmaceuticals

Otsuka Holdings

Genzyme Corporation

Clavis Pharma

Cephalon

Bristol Myers Squibb

Ambit Biosciences Corporation

Acute Myeloid Leukemia Drugs Segment by Type

Chemotherapy

Targeted Therapy

Other

Acute Myeloid Leukemia Drugs Segment by Application

Hospital

Clinic

Others

Acute Myeloid Leukemia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukemia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Acute Myeloid Leukemia Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Acute Myeloid Leukemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Acute Myeloid Leukemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Acute Myeloid Leukemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Acute Myeloid Leukemia Drugs Industry Trends Table 2. Acute Myeloid Leukemia Drugs Industry Drivers Table 3. Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges Table 4. Acute Myeloid Leukemia Drugs Industry Restraints Table 5. Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Acute Myeloid Leukemia Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers Table 9. Global Acute Myeloid Leukemia Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Acute Myeloid Leukemia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Acute Myeloid Leukemia Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Acute Myeloid Leukemia Drugs Manufacturers, Product Type & Application Table 13. Global Acute Myeloid Leukemia Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Acute Myeloid Leukemia Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Chemotherapy Table 17. Major Manufacturers of Targeted Therapy Table 18. Major Manufacturers of Other Table 19. Global Acute Myeloid Leukemia Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 21. Global Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 22. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2026) Table 23. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2027-2032) Table 24. Global Acute Myeloid Leukemia Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (k units) Table 26. Global Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (k units) Table 27. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Others Table 32. Global Acute Myeloid Leukemia Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 34. Global Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 35. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2026) Table 36. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2027-2032) Table 37. Global Acute Myeloid Leukemia Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (k units) Table 39. Global Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (k units) Table 40. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2021-2026) Table 45. Global Acute Myeloid Leukemia Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Acute Myeloid Leukemia Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 49. North America Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 50. Europe Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 52. Europe Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 59. Global Acute Myeloid Leukemia Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Acute Myeloid Leukemia Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Acute Myeloid Leukemia Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2027-2032) Table 64. Takeda Pharmaceuticals Company Information Table 65. Takeda Pharmaceuticals Business Overview Table 66. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio Table 68. Takeda Pharmaceuticals Recent Development Table 69. Eisai Company Information Table 70. Eisai Business Overview Table 71. Eisai Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Eisai Acute Myeloid Leukemia Drugs Product Portfolio Table 73. Eisai Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Acute Myeloid Leukemia Drugs Product Portfolio Table 78. Novartis Recent Development Table 79. Eli Lilly and Company Company Information Table 80. Eli Lilly and Company Business Overview Table 81. Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio Table 83. Eli Lilly and Company Recent Development Table 84. Sunesis Pharmaceuticals Company Information Table 85. Sunesis Pharmaceuticals Business Overview Table 86. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio Table 88. Sunesis Pharmaceuticals Recent Development Table 89. Otsuka Holdings Company Information Table 90. Otsuka Holdings Business Overview Table 91. Otsuka Holdings Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio Table 93. Otsuka Holdings Recent Development Table 94. Genzyme Corporation Company Information Table 95. Genzyme Corporation Business Overview Table 96. Genzyme Corporation Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio Table 98. Genzyme Corporation Recent Development Table 99. Clavis Pharma Company Information Table 100. Clavis Pharma Business Overview Table 101. Clavis Pharma Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio Table 103. Clavis Pharma Recent Development Table 104. Cephalon Company Information Table 105. Cephalon Business Overview Table 106. Cephalon Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Cephalon Acute Myeloid Leukemia Drugs Product Portfolio Table 108. Cephalon Recent Development Table 109. Bristol Myers Squibb Company Information Table 110. Bristol Myers Squibb Business Overview Table 111. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio Table 113. Bristol Myers Squibb Recent Development Table 114. Ambit Biosciences Corporation Company Information Table 115. Ambit Biosciences Corporation Business Overview Table 116. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio Table 118. Ambit Biosciences Corporation Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Acute Myeloid Leukemia Drugs Distributors List Table 122. Acute Myeloid Leukemia Drugs Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Acute Myeloid Leukemia Drugs Product Image Figure 2. Global Acute Myeloid Leukemia Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Myeloid Leukemia Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Myeloid Leukemia Drugs Sales (2021-2032) & (k units) Figure 5. Global Acute Myeloid Leukemia Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Acute Myeloid Leukemia Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Chemotherapy Image Figure 9. Targeted Therapy Image Figure 10. Other Image Figure 11. Global Acute Myeloid Leukemia Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Acute Myeloid Leukemia Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Acute Myeloid Leukemia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Acute Myeloid Leukemia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Acute Myeloid Leukemia Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Acute Myeloid Leukemia Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Acute Myeloid Leukemia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Acute Myeloid Leukemia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Acute Myeloid Leukemia Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Acute Myeloid Leukemia Drugs Sales Market Share by Country (2021-2032) Figure 40. China Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Acute Myeloid Leukemia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Acute Myeloid Leukemia Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Acute Myeloid Leukemia Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Acute Myeloid Leukemia Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Eisai
  • Novartis
  • Eli Lilly and Company
  • Sunesis Pharmaceuticals
  • Otsuka Holdings
  • Genzyme Corporation
  • Clavis Pharma
  • Cephalon
  • Bristol Myers Squibb
  • Ambit Biosciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acute Myeloid Leukemia Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acute Myeloid Leukemia Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Acute Myeloid Leukemia Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Acute Myeloid Leukemia Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Acute Myeloid Leukemia Drugs Market Dynamics
  1. 2.1 Acute Myeloid Leukemia Drugs Industry Trends
  2. 2.2 Acute Myeloid Leukemia Drugs Industry Drivers
  3. 2.3 Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Myeloid Leukemia Drugs Industry Restraints
3 Acute Myeloid Leukemia Drugs Market by Manufacturers
  1. 3.1 Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Acute Myeloid Leukemia Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Acute Myeloid Leukemia Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Acute Myeloid Leukemia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Acute Myeloid Leukemia Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Acute Myeloid Leukemia Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Acute Myeloid Leukemia Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Acute Myeloid Leukemia Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Acute Myeloid Leukemia Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Acute Myeloid Leukemia Drugs Tier 1, Tier 2, and Tier 3
4 Acute Myeloid Leukemia Drugs Market by Type
  1. 4.1 Acute Myeloid Leukemia Drugs Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Targeted Therapy
  4. 4.1.3 Other
  5. 4.2 Global Acute Myeloid Leukemia Drugs Sales by Type
  6. 4.2.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Acute Myeloid Leukemia Drugs Revenue by Type
  10. 4.3.1 Global Acute Myeloid Leukemia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2032)
5 Acute Myeloid Leukemia Drugs Market by Application
  1. 5.1 Acute Myeloid Leukemia Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Acute Myeloid Leukemia Drugs Sales by Application
  6. 5.2.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Acute Myeloid Leukemia Drugs Revenue by Application
  10. 5.3.1 Global Acute Myeloid Leukemia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2032)
6 Global Acute Myeloid Leukemia Drugs Sales by Region
  1. 6.1 Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Acute Myeloid Leukemia Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Acute Myeloid Leukemia Drugs Revenue by Region
  1. 7.1 Global Acute Myeloid Leukemia Drugs Revenue by Region
  2. 7.1.1 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Acute Myeloid Leukemia Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Acute Myeloid Leukemia Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Acute Myeloid Leukemia Drugs Revenue (2021-2032)
  8. 7.2.2 North America Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Acute Myeloid Leukemia Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Acute Myeloid Leukemia Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Acute Myeloid Leukemia Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Acute Myeloid Leukemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Acute Myeloid Leukemia Drugs Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Acute Myeloid Leukemia Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Eli Lilly and Company
  20. 8.4.1 Eli Lilly and Company Company Information
  21. 8.4.2 Eli Lilly and Company Business Overview
  22. 8.4.3 Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio
  24. 8.4.5 Eli Lilly and Company Recent Developments
  25. 8.5 Sunesis Pharmaceuticals
  26. 8.5.1 Sunesis Pharmaceuticals Company Information
  27. 8.5.2 Sunesis Pharmaceuticals Business Overview
  28. 8.5.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
  30. 8.5.5 Sunesis Pharmaceuticals Recent Developments
  31. 8.6 Otsuka Holdings
  32. 8.6.1 Otsuka Holdings Company Information
  33. 8.6.2 Otsuka Holdings Business Overview
  34. 8.6.3 Otsuka Holdings Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio
  36. 8.6.5 Otsuka Holdings Recent Developments
  37. 8.7 Genzyme Corporation
  38. 8.7.1 Genzyme Corporation Company Information
  39. 8.7.2 Genzyme Corporation Business Overview
  40. 8.7.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio
  42. 8.7.5 Genzyme Corporation Recent Developments
  43. 8.8 Clavis Pharma
  44. 8.8.1 Clavis Pharma Company Information
  45. 8.8.2 Clavis Pharma Business Overview
  46. 8.8.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio
  48. 8.8.5 Clavis Pharma Recent Developments
  49. 8.9 Cephalon
  50. 8.9.1 Cephalon Company Information
  51. 8.9.2 Cephalon Business Overview
  52. 8.9.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cephalon Acute Myeloid Leukemia Drugs Product Portfolio
  54. 8.9.5 Cephalon Recent Developments
  55. 8.10 Bristol Myers Squibb
  56. 8.10.1 Bristol Myers Squibb Company Information
  57. 8.10.2 Bristol Myers Squibb Business Overview
  58. 8.10.3 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio
  60. 8.10.5 Bristol Myers Squibb Recent Developments
  61. 8.11 Ambit Biosciences Corporation
  62. 8.11.1 Ambit Biosciences Corporation Company Information
  63. 8.11.2 Ambit Biosciences Corporation Business Overview
  64. 8.11.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio
  66. 8.11.5 Ambit Biosciences Corporation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Acute Myeloid Leukemia Drugs Value Chain Analysis
  2. 9.1.1 Acute Myeloid Leukemia Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Acute Myeloid Leukemia Drugs Production Mode & Process
  6. 9.2 Acute Myeloid Leukemia Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Acute Myeloid Leukemia Drugs Distributors
  9. 9.2.3 Acute Myeloid Leukemia Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst